Skip to main content
. 2016 Feb 22;7(14):18229–18246. doi: 10.18632/oncotarget.7571

Figure 2. L-FABP promotes VEGF-A expression and angiogenic activity of liver cells.

Figure 2

A. Western blot analysis for L-FABP expression in normal immortalized hepatocyte (Hus) and hepatocellular carcinoma (HepG2, Hep3B, Huh7 and PLC/PRF/5) cell lines. B. Angiogenic potential (score: see In vitro tube formation assay in Methods for details) of Hus, HepG2, Hep3B, Huh7, and PLC/PRF/5 cells. ***p < 0.001 versus Hus cells. C. Western blotting analysis of L-FABP and VEGF-A expression in Hus/L-FABP and Hus/Vector (vector-only control) cells. *p < 0.05 versus Hus/Vector control. D. In vitro angiogenic potential (score: see panel B) of Hus/L-FABP and Hus/Vector cells. Angiogenic vascular tube was imaged at 8 h. ***p < 0.001 versus Hus/Vector control. E. In vivo angiogenic activity of Hus/L-FABP and Hus/Vector cells assessed using a Matrigel plug assay. a: Matrigel plugs recovered from mice injected with Hus/Vector and Hus/L-FABP cells. Arrows indicate infiltration of blood vessels. b: Immunohistochemical (IHC) staining of CD31 (angiogenesis marker) in Matrigel plugs showed that Hus/L-FABP promoted angiogenesis, and the positively stained vessels are indicated by arrows. *p < 0.05 versus Hus/Vector control (n = 3).

HHS Vulnerability Disclosure